Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT01363427
  4. Details
NCT01363427 Clinical Trial

Retrospective Data Analysis in Crohn's Disease

Crohn's Disease Clinical Trial

— Crohn 2  

Official title:
Retrospective Data Analysis of Newly Diagnosed Crohn's Disease Patients in Gastroenterological Surgeries

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01363427
Other study ID # FE 999907 (Pentasa)
Secondary ID
Status Completed
Phase N/A
First received May 30, 2011
Last updated May 31, 2011
Start date March 2007
Est. completion date July 2010

Study information
Verified date May 2011
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Observational

Clinical Trial Summary

The purpose of this study is to identify prognostic parameters about efficacy of Mesalazine in recently diagnosed patients with Morbus Crohn by retrospective data collection.

Recruitment information / eligibility
Status Completed
Enrollment 161
Est. completion date July 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- therapeutic need according to SPC

- written informed consent

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
Germany Investigational Site, Ehrenfelsstraße 47 Berlin
Germany Investigational Site, Möllendorfstraße 111 Berlin
Germany Investigational Site, Münchner Straße 64 Dachau
Germany Investigational Site, Karlsbader Straße 7 Dinkelsbühl
Germany Investigational Site, Heiligengrabstraße 16 Hof
Germany Investigational Site, Am Tiefen Weg 2 Karlstadt
Germany Investigational Site, Erdbeerfeld 8 Kiel-Altenholz
Germany Investigational Site, Hohenfelder Straße 20 Koblenz
Germany Investigational Site, Graseggerstraße 105 Köln
Germany Investigational Site, Funkenburgstraße 19 Leipzig
Germany Investigational Site, Franz-Kail-Straße 2 Leverkusen
Germany Investigational Site, Bahnhofplatz 2 Mainz
Germany Investigational Site, Uferstraße 3 Minden
Germany Investigational Site, Hammer Straße 95 Münster
Germany Investigational Site, Weiltinger Str. 11 Nürnberg
Germany Investigational Site, Marktplatz 23 Rottenburg

Sponsors (1)
Lead Sponsor Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Response to Mesalazine: measured by time to step up therapy 12 to 48 months No
Secondary Identification and characterisation of the responding sub-population measured by: (a) Age at diagnosis, (b) Proportion of patients with minor endoscopic lesions, (c) Lack of severe mucosal lesions (Adapted Rutgeerts Score < 2) 12 to 48 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01958827 - A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Phase 3